|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500101594 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-27 11:45:40 |
|
注册时间: Date of Registration: |
2025-04-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
迷走神经磁刺激对脑损伤后认知功能障碍的疗效及分析 |
|
Public title: |
Efficacy and analysis of vagus nerve magnetic stimulation on cognitive dysfunction after brain injury |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
迷走神经磁刺激对脑损伤后认知功能障碍的疗效及分析 |
|
Scientific title: |
Efficacy and analysis of vagus nerve magnetic stimulation on cognitive dysfunction after brain injury |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵余 |
研究负责人: |
张晗 |
|
Applicant: |
Zhao Yu |
Study leader: |
Zhang Han |
|
申请注册联系人电话: Applicant telephone: |
+86 184 0827 0872 |
研究负责人电话:
Study leader's |
+86 182 8171 7788 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
742958989@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
18281717788@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省南充市高坪区万科一期 |
研究负责人通讯地址: |
四川省南充市人民南路97号 |
|
Applicant address: |
Vanke Phase I, Gaoping District, Nanchong City, Sichuan Province |
Study leader's address: |
No.97 Renmin Road South, Nanchong, Sichuan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南充市中心医院 |
||
|
Applicant's institution: |
Nanchong Central Hospital, Nanchong, China |
||
|
研究负责人所在单位: |
南充市中心医院 |
||
|
Affiliation of the Leader: |
Nanchong Central Hospital, Nanchong, China |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022年审(086)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南充市中心医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Nanchong Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-19 00:00:00 | ||
|
伦理委员会联系人: |
曾玲 |
||
|
Contact Name of the ethic committee: |
Zeng Ling |
||
|
伦理委员会联系地址: |
四川省南充市顺庆区人民南路97号 |
||
|
Contact Address of the ethic committee: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 817 271 2055 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南充市中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanchong Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省南充市顺庆区人民南路97号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.研究迷走神经磁刺激对脑卒中后患者认知功能的影响;2.利用功能性近红外光谱检测脑卒中患者在迷走神经磁刺激干预前后的大脑变化以探讨其认知恢复的潜在机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To study the effect of vagus nerve magnetic stimulation on the cognitive function of patients after stroke; 2.Functional near-infrared spectroscopy was used to detect the brain changes of stroke patients before and after vagus nerve magnetic stimulation intervention to explore the potential mechanism of cognitive recovery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①根据《中国急性脑出血诊断和治疗指南(2019)》和《中国急性缺血性脑卒中诊断和治疗指南(2018)》,患者确诊为脑卒中,并均经头颅CT或MRI扫描证实; ②首次脑卒中,病程为1至6月; ③右利手; ④年龄18—70岁; ⑤存在认知障碍,蒙特利尔认知评估量表(Montreal cognitive assessment,MoCA-B评分<26分; ⑥无严重失语并且能完成认知测试; ⑦生命体征稳定,无进展的神经症状; ⑧自愿参加并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.According to the Chinese Guidelines for the Diagnosis and Treatment of Acute Intracerebral Hemorrhage (2019) and the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2018), the patient was diagnosed with stroke, and both were confirmed by head CT or MRI scans; 2.The first stroke, the course of which lasted from 1 to 6 months; 3, Right-handed; 4. Age 18-70 years old; 5. Cognitive impairment, Montreal cognitive assessment, MoCA-B score< 26 points; 6. No severe aphasia and able to complete cognitive tests; 7. Stable vital signs without progressive neurological symptoms; 8. Voluntarily participate and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
①非首次卒中; ②左额叶完全损伤; ③体内有金属植入物、心脏起搏器不能进行VNMS治疗等; ④既往有脑肿瘤、脑外伤、癫痫病史及癫痫发作风险; ⑤卒中前存在认知功能减退; ⑥任何神经精神疾病及明显的情感障碍可影响测试结果; ⑦任何影响评估及治疗的其他因素。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Non-first stroke; 2.Complete injury to the left frontal lobe; 3.There are metal implants in the body, cardiac pacemakers cannot be treated with VNMS, etc.; 4.History of brain tumor, traumatic brain injury, epilepsy and risk of seizures; 5.Cognitive decline before stroke; 6.Any neuropsychiatric disorder and obvious affective disorder can affect the test results; 7.Any other factors that affect the assessment and treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-01 00:00:00至 To 2024-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-07-13 00:00:00 至 To 2024-03-21 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
将入选受试者按顺序编号,采用SPSS软件进行随机化分配,并装入随机信件分配治疗 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The enrolled subjects were sequentially numbered, randomized using SPSS software, and loaded into randomized letter assignment treatments. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
由不参与实施治疗和评估的研究人员负责信封分配和保管。实验揭盲前,受试者、结局评估者和统计人员均不知道分组情况,当受试者纳入研究时按纳入顺序由干预者拆开与其序号相同的信封并根据其中分组方案治疗。 |
|
Blinding: |
Envelope distribution and storage will be undertaken by investigators who were not involved in administering the treatments and evaluations. Before the unblinding of the experiment, the subjects, outcome evaluators and statisticians were not aware of the grouping situation. When the subjects were included in the study, the interventionist opened the envelope with the same serial number and treated according to the grouping plan in it. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026-12-31; http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2026-12-31; http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |